HIV / AIDS

Investigators incorporated universal HIV screening into COVID-19 testing at a Chicago hospital emergency department (ED).

The ATLAS 2M study results showed non-inferiority in 2-month dosing compared to 1-month dosing for the cabotegravir and rilpivirine long-acting injectable.

A recent study looked at the racial disparities amongst people living with HIV and COVID-19 positivity rates.

2020 forced clinicians and people with HIV (PWH) to adapt to the COVID-19 pandemic. While initially it had an immediate impact on patient care, new solutions and strategies were created to ensure health care was delivered to those who needed it.

Two randomized trials involved more than 4500 patients to determine the efficacy of a broadly neutralizing antibody in blocking acquisition of HIV infection.

A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.

The phase 2b-3 trial analyzing the efficacy of the ALVAC–gp120 regimen showed that it did not prevent an HIV-1 infection among the participants in the study at 24 months.

Long-acting injectables for latent and active tuberculous (TB) might be a treatment option in the future and could open up the door to possibly bundling HIV and TB care together.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

Managing mental health in adults living with HIV is paramount during the COVID-19 pandemic.

Index testing declined in countries including Malawi, Lesotho and Zimbabwe.

Deep learning models identified the largest differences in resting state network topology occurred.

The prognostic proteins identified can serve as the basis of future pathway and network analyses.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

During the pandemic, reduced HIV testing led to concerns about getting people diagnosed and on antiretroviral therapy (ART), and achieving viral suppression (VS).

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

14 weeks of oral alendronate taken prior to ART had a sustained impact on prevention of bone loss at the hip.

Increased hospitalization risk was driven mainly by the high burden of comorbidities in both groups.

Change was associated with risk factors that have not been reported like chronic lung disease.

Merck’s islatravir subdermal implant demonstrated it achieved active drug concentrations above the pre-specified pharmacokinetics (pk) threshold at 12 weeks across three doses.

People with HIV had similar control of most conditions except for triglycerides.

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.